Anna Gisselsson
Direktor/Vorstandsmitglied bei Moroxite F AB
Profil
Anna Gisselsson is currently working as a Director at Moroxite F AB and as an Investment Manager at Almi Invest AB.
She has a graduate and doctorate degree from the Faculty of Engineering, Lund University.
Aktive Positionen von Anna Gisselsson
| Unternehmen | Position | Beginn |
|---|---|---|
Almi Invest AB
 Almi Invest AB Investment ManagersFinance Almi Invest AB (Almi) is a Venture Capital subsidiary of ALMI Företagspartner AB, founded in 2009. The firm is headquartered in Stockholm, Sweden. | Private Equity Investor | 01.11.2020 |
Moroxite F AB
 Moroxite F AB Miscellaneous Commercial ServicesCommercial Services Moroxite F AB has developed a regenerative medicine approach for fragility fractures, which improves implant anchorage and reduces fixation failures, re-operations, societal costs, and improves quality of life. The company is based in Lund, Sweden. The Swedish company has also developed an injectable platform for prolonged release of hydroxyapatite binding drugs in fragility fractures. | Direktor/Vorstandsmitglied | - |
Ausbildung von Anna Gisselsson
| Faculty of Engineering, Lund University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Almi Invest AB
Almi Invest AB Investment ManagersFinance Almi Invest AB (Almi) is a Venture Capital subsidiary of ALMI Företagspartner AB, founded in 2009. The firm is headquartered in Stockholm, Sweden. | Finance |
Moroxite F AB
Moroxite F AB Miscellaneous Commercial ServicesCommercial Services Moroxite F AB has developed a regenerative medicine approach for fragility fractures, which improves implant anchorage and reduces fixation failures, re-operations, societal costs, and improves quality of life. The company is based in Lund, Sweden. The Swedish company has also developed an injectable platform for prolonged release of hydroxyapatite binding drugs in fragility fractures. | Commercial Services |
